Xevinapant

Xevinapant
Clinical data
Other namesAT 406; Debio-1143
Legal status
Legal status
  • Investigational
Identifiers
  • (5S,8S,10aR)-N-benzhydryl-5-[[(2S)-2-(methylamino)propanoyl]amino]-3-(3-methylbutanoyl)-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC32H43N5O4
Molar mass561.727 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)CC(C)C)NC
  • InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
  • Key:LSXUTRRVVSPWDZ-MKKUMYSQSA-N

Xevinapant is an investigational new drug that is being evaluated to treat squamous cell cancer.[1] By acting as a SMAC mimetic, it functions as an inhibitor of several members of the IAP protein family (including XIAP, c-IAP1, and c-IAP2).[2]

References

  1. ^ "Xevinapant - Merck & Co". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Ferris RL, Harrington K, Schoenfeld JD, Tahara M, Esdar C, Salmio S, et al. (February 2023). "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck". Cancer Treatment Reviews. 113: 102492. doi:10.1016/j.ctrv.2022.102492. PMC 11227656. PMID 36640618.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.